secwatch.observer — SEC 8-K summary
======================================

Issuer:     FENNEC PHARMACEUTICALS INC. (FENC)
CIK:        0001211583
Form:       8-K
Filed at:   2023-04-04T23:59:59+00:00
Accession:  0001104659-23-041338
Event type: regulatory
Sentiment:  positive
Materiality: 0.85
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Fennec receives positive CHMP opinion for Pedmarqsi to prevent cisplatin-induced hearing loss in pediatric patients
--------------------------------------------------------------------------------

- CHMP recommends EU marketing authorization for Pedmarqsi (sodium thiosulfate) to prevent ototoxicity in pediatric patients aged 1 month to <18 years with localized solid tumors.
- Phase 3 trial SIOPEL 6 showed hearing loss in 28.6% with Pedmarqsi vs 56.4% with cisplatin alone (p=0.004).
- European Commission decision expected by early June 2023; Pedmarqsi is already FDA-approved as PEDMARK in the U.S.
- Approximately 5,000 children in Europe annually eligible for platinum-based chemotherapy could benefit from this therapy.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1211583/000110465923041338/0001104659-23-041338-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1211583/000110465923041338/tm2311156d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-041338

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer